Sharon Shacham
Directeur/Membre du Conseil chez ACRIVON THERAPEUTICS, INC.
Fortune : 165 800 $ au 30/04/2024
Profil
Sharon Shacham is the founder of Karyopharm Therapeutics, Inc., which was founded in 2008.
She held the title of President & Chief Scientific Officer from 2015 to 2021.
Dr. Shacham is also currently working as an Independent Director at Acrivon Therapeutics, Inc. since 2020.
In her former positions, Dr. Shacham worked as a Director of Algorithm & Software Development at Predix Pharmaceuticals, Inc. She also served as the Senior Vice President of Drug Development at EPIX Pharmaceuticals, Inc. from 2000 to 2009.
Dr. Shacham's education includes undergraduate, MBA, and doctorate degrees from Tel-Aviv University.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 22/04/2024 | 19 575 ( 0,06% ) | 165 800 $ | 30/04/2024 |
Postes actifs de Sharon Shacham
| Sociétés | Poste | Début |
|---|---|---|
| ACRIVON THERAPEUTICS, INC. | Directeur/Membre du Conseil | 01/10/2020 |
Anciens postes connus de Sharon Shacham
| Sociétés | Poste | Fin |
|---|---|---|
| KARYOPHARM THERAPEUTICS INC. | Fondateur | 03/05/2021 |
EPIX Pharmaceuticals, Inc.
 EPIX Pharmaceuticals, Inc. Medical SpecialtiesHealth Technology EPIX Pharmaceuticals, Inc. used to develop targeted contrast agents both to improve the capability and expand the use of magnetic resonance imaging (MRI) as a tool for diagnosing human disease. The company was founded in 1988 and was headquartered in Lexington, MA. | Corporate Officer/Principal | 01/04/2009 |
Predix Pharmaceuticals, Inc.
 Predix Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Predix Pharmaceuticals, Inc. develops novel drugs and other related products. It is a clinical stage drug development company that uses proprietary discovery and lead optimization engine to develop novel drugs for G-protein coupled receptor (GPCR) and ion channel targets. The company was founded by Silvia Noiman, Haim Aviv, Oren M. Becker and Oren M. Ramot in September, 2002 and is headquartered in Woburn, MA. | Corporate Officer/Principal | - |
Formation de Sharon Shacham
| Tel-Aviv University | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| KARYOPHARM THERAPEUTICS INC. | Health Technology |
| ACRIVON THERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 2 |
|---|---|
EPIX Pharmaceuticals, Inc.
EPIX Pharmaceuticals, Inc. Medical SpecialtiesHealth Technology EPIX Pharmaceuticals, Inc. used to develop targeted contrast agents both to improve the capability and expand the use of magnetic resonance imaging (MRI) as a tool for diagnosing human disease. The company was founded in 1988 and was headquartered in Lexington, MA. | Health Technology |
Predix Pharmaceuticals, Inc.
Predix Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Predix Pharmaceuticals, Inc. develops novel drugs and other related products. It is a clinical stage drug development company that uses proprietary discovery and lead optimization engine to develop novel drugs for G-protein coupled receptor (GPCR) and ion channel targets. The company was founded by Silvia Noiman, Haim Aviv, Oren M. Becker and Oren M. Ramot in September, 2002 and is headquartered in Woburn, MA. | Health Technology |